<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02066129</url>
  </required_header>
  <id_info>
    <org_study_id>AsthmaNet 008</org_study_id>
    <nct_id>NCT02066129</nct_id>
  </id_info>
  <brief_title>Step-up Yellow Zone Inhaled Corticosteroids to Prevent Exacerbations</brief_title>
  <acronym>STICS</acronym>
  <official_title>Step-up Yellow Zone Inhaled Corticosteroids to Prevent Exacerbations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Milton S. Hershey Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Milton S. Hershey Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to determine whether, in children receiving low-dose inhaled
      corticosteroids (ICS), quintupling the dose of inhaled corticosteroids at the onset of
      symptoms previously associated with upper respiratory illnesses and subsequent asthma
      exacerbations reduces the rate of severe asthma exacerbations treated with oral
      corticosteroids.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study design is a double-blind, parallel-group trial, including a total of 250
      participants, ages 5-11 years, with a diagnosis of asthma and a history of at least 1 asthma
      exacerbation treated with oral corticosteroids in the prior year. All participants will be
      treated for 48 weeks with open-label fluticasone 44 mcg 2 puffs twice daily. During the
      48-week treatment period, participants will receive randomized blinded therapy for 7 days
      each time they enter the &quot;yellow zone&quot; (at the onset of symptoms previously associated with
      upper respiratory illnesses and subsequent asthma exacerbations). Yellow zone therapy will be
      fluticasone 44 or 220 mcg 2 puffs twice daily.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2014</start_date>
  <completion_date type="Actual">April 21, 2017</completion_date>
  <primary_completion_date type="Actual">April 21, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Asthma Exacerbations</measure>
    <time_frame>end of 48 week treatment period</time_frame>
    <description>The primary outcome is the rate of severe asthma exacerbations treated with oral corticosteroids during the 48 week treatment period.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Yellow Zone Asthma Symptoms</measure>
    <time_frame>end of 48 week treatment period</time_frame>
    <description>Study participants completed a daily symptom diary. They scored the following diary elements on a scale from 0-3 (none-severe): Cough, Wheeze, Trouble Breathing, Interference With Activities. A combined score was calculated as the sum of the 4 elements and ranged from 0 to 12. The study intervention was based on yellow-zones as noted in the Study Description. This outcome was based on diary data including 21 days, beginning 7 days prior to the onset of the yellow-zone intervention and ending 14 days after the onset of the intervention. The total symptom burden outcome was defined as the sum of the combined score on each diary day and ranged from 0 to 252 (max combined score of 12 per day multiplied by 21 days). A score of zero would indicate no symptoms over the entire 21 days. A score of 252 would indicate severe cough, wheeze, shortness of breath, and interference with activities on all of the 21 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Yellow Zone Albuterol Use</measure>
    <time_frame>end of 48 week treatment period</time_frame>
    <description>Use of albuterol rescue medication during 7-day yellow zone episodes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Unscheduled Emergency Department (ED) or Urgent Care Visits for Asthma</measure>
    <time_frame>end of 48 week treatment period</time_frame>
    <description>Rate of emergency department (ED) or urgent care visits for asthma during the 48 week treatment period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Hospitalized for Asthma</measure>
    <time_frame>end of 48 week treatment period</time_frame>
    <description>Number of participants hospitalized for asthma during the 48 week treatment period.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">254</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Fluticasone 44 mcg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Fluticasone 44 mcg 2 puffs twice daily for 7 days initiated at the onset of &quot;yellow zone&quot; symptoms.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fluticasone 220 mcg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Fluticasone 220 mcg 2 puffs twice daily for 7 days initiated at the onset of &quot;yellow zone&quot; symptoms.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluticasone 44 mcg</intervention_name>
    <description>Fluticasone is an inhaled corticosteroid</description>
    <arm_group_label>Fluticasone 44 mcg</arm_group_label>
    <other_name>Flovent® 44 mcg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluticasone 220 mcg</intervention_name>
    <description>Fluticasone is an inhaled corticosteroid</description>
    <arm_group_label>Fluticasone 220 mcg</arm_group_label>
    <other_name>Flovent® 220 mcg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Physician-diagnosed asthma

          -  At least 1 exacerbation treated with systemic (oral or injectable) corticosteroids in
             the past 12 months

          -  Able to perform reproducible spirometry

          -  Current treatment with step 2 controller therapy [low-dose ICS, leukotriene receptor
             antagonist (LTRA)] OR current treatment with step 3 controller therapy [low-dose ICS +
             long-acting beta agonist (LABA), low-dose ICS + LTRA, or medium dose ICS] with a
             childhood Asthma Control Test (c-ACT) score of &gt;19, no more than 2 prednisone treated
             exacerbations in the past 6 months, prebronchodilator Forced Expiratory Volume at 1
             second (FEV1) ≥ 80% predicted and willing to step down therapy OR controller naïve and
             qualifying for step 2 controller therapy [asthma symptoms or short acting beta agonist
             (SABA) use &gt; 2 days per week or night-time awakenings due to asthma &gt; 2 nights per
             month]

          -  Prebronchodilator FEV1 ≥ 60% predicted

          -  Ability and willingness to provide informed assent

          -  For females of childbearing potential: not pregnant, non-lactating, and agree to
             practice an adequate birth control method.

          -  History of clinical varicella or varicella vaccine

        Exclusion Criteria:

          -  Systemic (oral or injectable) corticosteroids within previous 2-week period

          -  Current or recent (previous 2-weeks) use of medications known to significantly
             interact with corticosteroid disposition, including but not limited to carbamazepine,
             erythromycin, phenobarbital, phenytoin, rifampin, and ketoconazole

          -  Presence of chronic or active lung disease other than asthma

          -  Significant medical illness other than asthma, including thyroid disease, diabetes
             mellitus, Cushing's disease, Addison's disease, hepatic disease, or concurrent medical
             problems that could require oral corticosteroids during the study

          -  A history of cataracts, glaucoma, or any other medical disorder associated with an
             adverse effect to corticosteroids

          -  History of a life-threatening asthma exacerbation requiring intubation, mechanical
             ventilation, or resulting in a hypoxic seizure

          -  More than 5 prednisone treated exacerbations in the past 12 months

          -  More than 1 hospitalizations lasting &gt;24 hours for asthma in the past 12 months

          -  History of adverse reactions to ICS preparations or any of their ingredients

          -  Receiving hyposensitization therapy other than an established maintenance regimen (On
             maintenance regimen for ≥ 3 months)

          -  History of premature birth before 35 weeks gestation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>11 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William Busse, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Wisconsin, Madison</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Arizona College of Medicine</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital &amp; Research Center Oakland</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCSF Benioff Children's Hospital</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Jewish Health</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nemours Children's Clinic</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nemours Children's Clinic</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32827</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center/Stroger Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Illinois at Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ann and Robert H. Lurie Children's Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Boston</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Louis Children's Hospital</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Forest University Health Sciences</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rainbow Babies and Children's Hospital, Case Western Reserve University</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allegheny General Hospital</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Pittsburgh of UPMC</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53972</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://asthmanetresearch.org/</url>
    <description>AsthmaNet</description>
  </link>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>February 17, 2014</study_first_submitted>
  <study_first_submitted_qc>February 17, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 19, 2014</study_first_posted>
  <results_first_submitted>April 23, 2018</results_first_submitted>
  <results_first_submitted_qc>June 11, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">July 11, 2018</results_first_posted>
  <last_update_submitted>June 11, 2018</last_update_submitted>
  <last_update_submitted_qc>June 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Milton S. Hershey Medical Center</investigator_affiliation>
    <investigator_full_name>dave mauger</investigator_full_name>
    <investigator_title>Principal Investigator, AsthmaNet Data Coordinating Center</investigator_title>
  </responsible_party>
  <keyword>Asthma</keyword>
  <keyword>Fluticasone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluticasone</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 16, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/29/NCT02066129/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Fluticasone 44 mcg</title>
          <description>Fluticasone 44 mcg 2 puffs twice daily for 7 days initiated at the onset of &quot;yellow zone&quot; symptoms.
Fluticasone 44 mcg: Fluticasone is an inhaled corticosteroid</description>
        </group>
        <group group_id="P2">
          <title>Fluticasone 220 mcg</title>
          <description>Fluticasone 220 mcg 2 puffs twice daily for 7 days initiated at the onset of &quot;yellow zone&quot; symptoms.
Fluticasone 220 mcg: Fluticasone is an inhaled corticosteroid</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="127"/>
                <participants group_id="P2" count="127"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="98"/>
                <participants group_id="P2" count="94"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="33"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Fluticasone 44 mcg</title>
          <description>Fluticasone 44 mcg 2 puffs twice daily for 7 days initiated at the onset of &quot;yellow zone&quot; symptoms.
Fluticasone 44 mcg: Fluticasone is an inhaled corticosteroid</description>
        </group>
        <group group_id="B2">
          <title>Fluticasone 220 mcg</title>
          <description>Fluticasone 220 mcg 2 puffs twice daily for 7 days initiated at the onset of &quot;yellow zone&quot; symptoms.
Fluticasone 220 mcg: Fluticasone is an inhaled corticosteroid</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="127"/>
            <count group_id="B2" value="127"/>
            <count group_id="B3" value="254"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.9" spread="1.9"/>
                    <measurement group_id="B2" value="8.1" spread="1.8"/>
                    <measurement group_id="B3" value="8.0" spread="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="91"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="80"/>
                    <measurement group_id="B2" value="83"/>
                    <measurement group_id="B3" value="163"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64"/>
                    <measurement group_id="B2" value="76"/>
                    <measurement group_id="B3" value="140"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="127"/>
                    <measurement group_id="B2" value="127"/>
                    <measurement group_id="B3" value="254"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Blood eosinophils</title>
          <units>cells per cubic millimeter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="367" spread="300"/>
                    <measurement group_id="B2" value="327" spread="234"/>
                    <measurement group_id="B3" value="346" spread="268"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of positive allergen specific IgE tests</title>
          <units>count</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.8" spread="4.2"/>
                    <measurement group_id="B2" value="5.2" spread="4.5"/>
                    <measurement group_id="B3" value="5.0" spread="4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hospitalized in year prior to enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Post albuterol forced expiratory volume at one second (FEV1) % of predicted</title>
          <description>FEV1 following 4 puffs of albuterol, expressed as percent of predicted (based on age, sex, race, and height).</description>
          <units>percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="106.8" spread="15.6"/>
                    <measurement group_id="B2" value="107.8" spread="13.9"/>
                    <measurement group_id="B3" value="107.3" spread="14.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>At least one allergen specific immunoglobulin E (IgE) tests</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="88"/>
                    <measurement group_id="B2" value="99"/>
                    <measurement group_id="B3" value="187"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Asthma Exacerbations</title>
        <description>The primary outcome is the rate of severe asthma exacerbations treated with oral corticosteroids during the 48 week treatment period.</description>
        <time_frame>end of 48 week treatment period</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Fluticasone 44 mcg</title>
            <description>Fluticasone 44 mcg 2 puffs twice daily for 7 days initiated at the onset of &quot;yellow zone&quot; symptoms.
Fluticasone 44 mcg: Fluticasone is an inhaled corticosteroid</description>
          </group>
          <group group_id="O2">
            <title>Fluticasone 220 mcg</title>
            <description>Fluticasone 220 mcg 2 puffs twice daily for 7 days initiated at the onset of &quot;yellow zone&quot; symptoms.
Fluticasone 220 mcg: Fluticasone is an inhaled corticosteroid</description>
          </group>
        </group_list>
        <measure>
          <title>Asthma Exacerbations</title>
          <description>The primary outcome is the rate of severe asthma exacerbations treated with oral corticosteroids during the 48 week treatment period.</description>
          <units>exacerbations per year</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="127"/>
                <count group_id="O2" value="127"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.37" lower_limit="0.25" upper_limit="0.55"/>
                    <measurement group_id="O2" value="0.48" lower_limit="0.33" upper_limit="0.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Yellow Zone Asthma Symptoms</title>
        <description>Study participants completed a daily symptom diary. They scored the following diary elements on a scale from 0-3 (none-severe): Cough, Wheeze, Trouble Breathing, Interference With Activities. A combined score was calculated as the sum of the 4 elements and ranged from 0 to 12. The study intervention was based on yellow-zones as noted in the Study Description. This outcome was based on diary data including 21 days, beginning 7 days prior to the onset of the yellow-zone intervention and ending 14 days after the onset of the intervention. The total symptom burden outcome was defined as the sum of the combined score on each diary day and ranged from 0 to 252 (max combined score of 12 per day multiplied by 21 days). A score of zero would indicate no symptoms over the entire 21 days. A score of 252 would indicate severe cough, wheeze, shortness of breath, and interference with activities on all of the 21 days.</description>
        <time_frame>end of 48 week treatment period</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Fluticasone 44 mcg</title>
            <description>Fluticasone 44 mcg 2 puffs twice daily for 7 days initiated at the onset of &quot;yellow zone&quot; symptoms.
Fluticasone 44 mcg: Fluticasone is an inhaled corticosteroid</description>
          </group>
          <group group_id="O2">
            <title>Fluticasone 220 mcg</title>
            <description>Fluticasone 220 mcg 2 puffs twice daily for 7 days initiated at the onset of &quot;yellow zone&quot; symptoms.
Fluticasone 220 mcg: Fluticasone is an inhaled corticosteroid</description>
          </group>
        </group_list>
        <measure>
          <title>Yellow Zone Asthma Symptoms</title>
          <description>Study participants completed a daily symptom diary. They scored the following diary elements on a scale from 0-3 (none-severe): Cough, Wheeze, Trouble Breathing, Interference With Activities. A combined score was calculated as the sum of the 4 elements and ranged from 0 to 12. The study intervention was based on yellow-zones as noted in the Study Description. This outcome was based on diary data including 21 days, beginning 7 days prior to the onset of the yellow-zone intervention and ending 14 days after the onset of the intervention. The total symptom burden outcome was defined as the sum of the combined score on each diary day and ranged from 0 to 252 (max combined score of 12 per day multiplied by 21 days). A score of zero would indicate no symptoms over the entire 21 days. A score of 252 would indicate severe cough, wheeze, shortness of breath, and interference with activities on all of the 21 days.</description>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="127"/>
                <count group_id="O2" value="127"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20" lower_limit="17" upper_limit="24"/>
                    <measurement group_id="O2" value="23" lower_limit="19" upper_limit="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Yellow Zone Albuterol Use</title>
        <description>Use of albuterol rescue medication during 7-day yellow zone episodes.</description>
        <time_frame>end of 48 week treatment period</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Fluticasone 44 mcg</title>
            <description>Fluticasone 44 mcg 2 puffs twice daily for 7 days initiated at the onset of &quot;yellow zone&quot; symptoms.
Fluticasone 44 mcg: Fluticasone is an inhaled corticosteroid</description>
          </group>
          <group group_id="O2">
            <title>Fluticasone 220 mcg</title>
            <description>Fluticasone 220 mcg 2 puffs twice daily for 7 days initiated at the onset of &quot;yellow zone&quot; symptoms.
Fluticasone 220 mcg: Fluticasone is an inhaled corticosteroid</description>
          </group>
        </group_list>
        <measure>
          <title>Yellow Zone Albuterol Use</title>
          <description>Use of albuterol rescue medication during 7-day yellow zone episodes.</description>
          <units>number of albuterol puffs</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="127"/>
                <count group_id="O2" value="127"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13" lower_limit="11" upper_limit="16"/>
                    <measurement group_id="O2" value="15" lower_limit="13" upper_limit="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Unscheduled Emergency Department (ED) or Urgent Care Visits for Asthma</title>
        <description>Rate of emergency department (ED) or urgent care visits for asthma during the 48 week treatment period.</description>
        <time_frame>end of 48 week treatment period</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Fluticasone 44 mcg</title>
            <description>Fluticasone 44 mcg 2 puffs twice daily for 7 days initiated at the onset of &quot;yellow zone&quot; symptoms.
Fluticasone 44 mcg: Fluticasone is an inhaled corticosteroid</description>
          </group>
          <group group_id="O2">
            <title>Fluticasone 220 mcg</title>
            <description>Fluticasone 220 mcg 2 puffs twice daily for 7 days initiated at the onset of &quot;yellow zone&quot; symptoms.
Fluticasone 220 mcg: Fluticasone is an inhaled corticosteroid</description>
          </group>
        </group_list>
        <measure>
          <title>Unscheduled Emergency Department (ED) or Urgent Care Visits for Asthma</title>
          <description>Rate of emergency department (ED) or urgent care visits for asthma during the 48 week treatment period.</description>
          <units>visits per year</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="127"/>
                <count group_id="O2" value="127"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.47" lower_limit="0.31" upper_limit="0.72"/>
                    <measurement group_id="O2" value="0.64" lower_limit="0.42" upper_limit="0.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Hospitalized for Asthma</title>
        <description>Number of participants hospitalized for asthma during the 48 week treatment period.</description>
        <time_frame>end of 48 week treatment period</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Fluticasone 44 mcg</title>
            <description>Fluticasone 44 mcg 2 puffs twice daily for 7 days initiated at the onset of &quot;yellow zone&quot; symptoms.
Fluticasone 44 mcg: Fluticasone is an inhaled corticosteroid</description>
          </group>
          <group group_id="O2">
            <title>Fluticasone 220 mcg</title>
            <description>Fluticasone 220 mcg 2 puffs twice daily for 7 days initiated at the onset of &quot;yellow zone&quot; symptoms.
Fluticasone 220 mcg: Fluticasone is an inhaled corticosteroid</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Hospitalized for Asthma</title>
          <description>Number of participants hospitalized for asthma during the 48 week treatment period.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="127"/>
                <count group_id="O2" value="127"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>48 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Fluticasone 44 mcg</title>
          <description>Fluticasone 44 mcg 2 puffs twice daily for 7 days initiated at the onset of &quot;yellow zone&quot; symptoms.
Fluticasone 44 mcg: Fluticasone is an inhaled corticosteroid</description>
        </group>
        <group group_id="E2">
          <title>Fluticasone 220 mcg</title>
          <description>Fluticasone 220 mcg 2 puffs twice daily for 7 days initiated at the onset of &quot;yellow zone&quot; symptoms.
Fluticasone 220 mcg: Fluticasone is an inhaled corticosteroid</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>ICD-9</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma Exacerbation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Hypertrophy Tonsils/Adenoids</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>ICD-9</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="115" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="111" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="45" subjects_affected="29" subjects_at_risk="127"/>
                <counts group_id="E2" events="49" subjects_affected="30" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="39" subjects_affected="24" subjects_at_risk="127"/>
                <counts group_id="E2" events="28" subjects_affected="21" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="22" subjects_affected="15" subjects_at_risk="127"/>
                <counts group_id="E2" events="12" subjects_affected="10" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Throat pain</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="127"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Vomiting alone</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="127"/>
                <counts group_id="E2" events="14" subjects_affected="10" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infectious enteritis</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="127"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Strep sore throat</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="127"/>
                <counts group_id="E2" events="16" subjects_affected="10" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" events="17" subjects_affected="14" subjects_at_risk="127"/>
                <counts group_id="E2" events="20" subjects_affected="14" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute nasopharyngitis</sub_title>
                <counts group_id="E1" events="99" subjects_affected="46" subjects_at_risk="127"/>
                <counts group_id="E2" events="57" subjects_affected="33" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Acute respiratory tract infection</sub_title>
                <counts group_id="E1" events="39" subjects_affected="22" subjects_at_risk="127"/>
                <counts group_id="E2" events="41" subjects_affected="21" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Acute sinusitis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="127"/>
                <counts group_id="E2" events="9" subjects_affected="7" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Allergic rhinitis</sub_title>
                <counts group_id="E1" events="62" subjects_affected="36" subjects_at_risk="127"/>
                <counts group_id="E2" events="45" subjects_affected="28" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" events="11" subjects_affected="8" subjects_at_risk="127"/>
                <counts group_id="E2" events="8" subjects_affected="6" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Acute asthma attack</sub_title>
                <counts group_id="E1" events="32" subjects_affected="25" subjects_at_risk="127"/>
                <counts group_id="E2" events="37" subjects_affected="30" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>David Mauger, PhD</name_or_title>
      <organization>Penn State University Dept of Public Health Sciences</organization>
      <phone>717.531.3584</phone>
      <email>dmauger@psu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

